RU2016127327A - Смесь пептидов - Google Patents
Смесь пептидов Download PDFInfo
- Publication number
- RU2016127327A RU2016127327A RU2016127327A RU2016127327A RU2016127327A RU 2016127327 A RU2016127327 A RU 2016127327A RU 2016127327 A RU2016127327 A RU 2016127327A RU 2016127327 A RU2016127327 A RU 2016127327A RU 2016127327 A RU2016127327 A RU 2016127327A
- Authority
- RU
- Russia
- Prior art keywords
- peptide
- ras protein
- peptides
- mixture
- mutation
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 119
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 40
- 239000000203 mixture Substances 0.000 title claims 36
- 230000035772 mutation Effects 0.000 claims 70
- 102000016914 ras Proteins Human genes 0.000 claims 46
- 108010014186 ras Proteins Proteins 0.000 claims 46
- 210000001744 T-lymphocyte Anatomy 0.000 claims 28
- 150000001413 amino acids Chemical class 0.000 claims 21
- 125000000539 amino acid group Chemical group 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 230000028993 immune response Effects 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 102200006657 rs104894228 Human genes 0.000 claims 6
- 229960005486 vaccine Drugs 0.000 claims 6
- 102200006533 rs121913535 Human genes 0.000 claims 5
- 230000004936 stimulating effect Effects 0.000 claims 5
- 102200006537 rs121913529 Human genes 0.000 claims 4
- 102200006540 rs121913530 Human genes 0.000 claims 4
- 102200006541 rs121913530 Human genes 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 102200006532 rs112445441 Human genes 0.000 claims 3
- 102220014333 rs112445441 Human genes 0.000 claims 3
- 102200006520 rs121913240 Human genes 0.000 claims 3
- 102200006525 rs121913240 Human genes 0.000 claims 3
- 102200006531 rs121913529 Human genes 0.000 claims 3
- 102200006539 rs121913529 Human genes 0.000 claims 3
- 102200006538 rs121913530 Human genes 0.000 claims 3
- 102200007373 rs17851045 Human genes 0.000 claims 3
- 102200006648 rs28933406 Human genes 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 102220117341 rs11554290 Human genes 0.000 claims 2
- 102220197780 rs121434596 Human genes 0.000 claims 2
- 102220197778 rs121913254 Human genes 0.000 claims 2
- 102220197834 rs121913535 Human genes 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13196333 | 2013-12-09 | ||
| EP13196333.2 | 2013-12-09 | ||
| PCT/EP2014/077033 WO2015086590A2 (en) | 2013-12-09 | 2014-12-09 | A peptide mixture |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2016127327A true RU2016127327A (ru) | 2018-01-23 |
Family
ID=49765823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016127327A RU2016127327A (ru) | 2013-12-09 | 2014-12-09 | Смесь пептидов |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US9775892B2 (enExample) |
| EP (5) | EP3363458A3 (enExample) |
| JP (2) | JP6781403B2 (enExample) |
| KR (1) | KR20160097290A (enExample) |
| CN (1) | CN105980403A (enExample) |
| AU (2) | AU2014363643B2 (enExample) |
| BR (1) | BR112016013138A2 (enExample) |
| CA (1) | CA2933126A1 (enExample) |
| CL (4) | CL2016001405A1 (enExample) |
| CY (1) | CY1120578T1 (enExample) |
| DK (1) | DK3079715T3 (enExample) |
| ES (1) | ES2682038T3 (enExample) |
| HR (1) | HRP20181213T1 (enExample) |
| HU (1) | HUE039840T2 (enExample) |
| IL (1) | IL246007B2 (enExample) |
| LT (1) | LT3079715T (enExample) |
| MX (1) | MX2016007429A (enExample) |
| PL (1) | PL3079715T3 (enExample) |
| PT (1) | PT3079715T (enExample) |
| RS (1) | RS57623B1 (enExample) |
| RU (1) | RU2016127327A (enExample) |
| SG (2) | SG10201811172PA (enExample) |
| SI (1) | SI3079715T1 (enExample) |
| WO (1) | WO2015086590A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9775892B2 (en) | 2013-12-09 | 2017-10-03 | Targovax Asa | Peptide mixture |
| CN106414493A (zh) | 2014-05-06 | 2017-02-15 | 塔格瓦克斯公司 | 包含突变的ras肽和化疗剂的肽疫苗 |
| EP3576780A1 (en) | 2017-02-01 | 2019-12-11 | Modernatx, Inc. | Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides |
| AU2018288386A1 (en) * | 2017-06-22 | 2020-02-06 | New South Wales Health Pathology | Adoptive T cell therapy 2 |
| CA3103983A1 (en) * | 2018-06-19 | 2019-12-26 | Biontech Us Inc. | Neoantigens and uses thereof |
| WO2020002650A1 (en) | 2018-06-29 | 2020-01-02 | Targovax Asa | A formulation |
| JP2021534752A (ja) * | 2018-08-22 | 2021-12-16 | フレッド ハッチンソン キャンサー リサーチ センター | Ｋｒａｓ抗原またはｈｅｒ２抗原を標的とする免疫療法 |
| GB2596461B (en) | 2019-02-20 | 2023-09-27 | Fred Hutchinson Cancer Center | Binding proteins specific for RAS neoantigens and uses thereof |
| WO2021009633A1 (en) * | 2019-07-12 | 2021-01-21 | Massey University | Synthetic chromatin vaccine |
| US12453774B2 (en) | 2019-11-07 | 2025-10-28 | Genoimmune Therapeutics Co., Ltd. | Tumor immunotherapy polypeptide and application thereof |
| CN113416241B (zh) * | 2020-04-09 | 2022-04-08 | 北京臻知医学科技有限责任公司 | 一种用于诱导肿瘤特异性免疫响应的通用型抗原肽库及试剂盒 |
| CN116710115A (zh) | 2020-11-20 | 2023-09-05 | 思维疗法股份有限公司 | 用于优化的肽疫苗的组合物和方法 |
| US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| KR102515083B1 (ko) | 2020-12-24 | 2023-03-29 | 부산대학교 산학협력단 | 폴더블 페로브스카이트 태양전지 및 이의 제조 방법 |
| EP4293043A4 (en) * | 2021-02-10 | 2025-09-10 | Shanghai Genbase Biotechnology Co Ltd | EPITOPE PEPTIDE OF THE RAS G13D MUTANT AND T LYMPHOCYTE RECEPTOR RECOGNIZING THE RAS G13D MUTANT |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
| EP4522192A2 (en) * | 2022-05-12 | 2025-03-19 | The Johns Hopkins University | Neoantigen vaccines for cancer prevention |
| JP2025538524A (ja) * | 2022-11-22 | 2025-11-28 | エリクサージェン セラピューティクス，インコーポレイティド | 癌免疫療法のための抗原 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9103974D0 (en) | 1991-02-26 | 1991-04-10 | Norsk Hydro As | Therapeutically useful peptides or peptide fragments |
| GB2328689A (en) * | 1997-08-27 | 1999-03-03 | Norsk Hydro As | Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer |
| NO309798B1 (no) * | 1999-04-30 | 2001-04-02 | Targovax As | Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen |
| AU2003301021C1 (en) | 2002-12-16 | 2010-02-18 | Globelmmune, Inc. | Yeast-based vaccines as immunotherapy |
| PL1760089T3 (pl) | 2005-09-05 | 2010-03-31 | Immatics Biotechnologies Gmbh | Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa |
| CN101448848B (zh) * | 2006-03-27 | 2013-12-04 | 全球免疫股份有限公司 | Ras突变及其相关组合物和方法 |
| US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| US9775892B2 (en) | 2013-12-09 | 2017-10-03 | Targovax Asa | Peptide mixture |
| CN106414493A (zh) | 2014-05-06 | 2017-02-15 | 塔格瓦克斯公司 | 包含突变的ras肽和化疗剂的肽疫苗 |
-
2014
- 2014-12-09 US US15/102,681 patent/US9775892B2/en not_active Expired - Fee Related
- 2014-12-09 KR KR1020167018341A patent/KR20160097290A/ko not_active Withdrawn
- 2014-12-09 ES ES14828148.8T patent/ES2682038T3/es active Active
- 2014-12-09 EP EP18166281.8A patent/EP3363458A3/en not_active Withdrawn
- 2014-12-09 CA CA2933126A patent/CA2933126A1/en not_active Abandoned
- 2014-12-09 SG SG10201811172PA patent/SG10201811172PA/en unknown
- 2014-12-09 PT PT148281488T patent/PT3079715T/pt unknown
- 2014-12-09 SG SG11201604644QA patent/SG11201604644QA/en unknown
- 2014-12-09 EP EP18164079.8A patent/EP3357505A1/en not_active Withdrawn
- 2014-12-09 MX MX2016007429A patent/MX2016007429A/es unknown
- 2014-12-09 WO PCT/EP2014/077033 patent/WO2015086590A2/en not_active Ceased
- 2014-12-09 PL PL14828148T patent/PL3079715T3/pl unknown
- 2014-12-09 DK DK14828148.8T patent/DK3079715T3/en active
- 2014-12-09 HU HUE14828148A patent/HUE039840T2/hu unknown
- 2014-12-09 RS RS20180907A patent/RS57623B1/sr unknown
- 2014-12-09 CN CN201480074531.3A patent/CN105980403A/zh active Pending
- 2014-12-09 EP EP14828148.8A patent/EP3079715B1/en active Active
- 2014-12-09 HR HRP20181213TT patent/HRP20181213T1/hr unknown
- 2014-12-09 EP EP18166279.2A patent/EP3363457A1/en not_active Withdrawn
- 2014-12-09 LT LTEP14828148.8T patent/LT3079715T/lt unknown
- 2014-12-09 AU AU2014363643A patent/AU2014363643B2/en not_active Ceased
- 2014-12-09 SI SI201430776T patent/SI3079715T1/en unknown
- 2014-12-09 JP JP2016557194A patent/JP6781403B2/ja active Active
- 2014-12-09 RU RU2016127327A patent/RU2016127327A/ru not_active Application Discontinuation
- 2014-12-09 BR BR112016013138-0A patent/BR112016013138A2/pt not_active Application Discontinuation
- 2014-12-09 EP EP18166278.4A patent/EP3369432A1/en not_active Withdrawn
-
2016
- 2016-06-02 IL IL246007A patent/IL246007B2/en unknown
- 2016-06-08 CL CL2016001405A patent/CL2016001405A1/es unknown
-
2017
- 2017-03-17 US US15/461,837 patent/US10335473B2/en active Active
- 2017-08-02 US US15/667,288 patent/US10456457B2/en active Active
- 2017-09-27 US US15/716,861 patent/US10596239B2/en active Active
-
2018
- 2018-01-26 CL CL2018000226A patent/CL2018000226A1/es unknown
- 2018-01-26 CL CL2018000238A patent/CL2018000238A1/es unknown
- 2018-01-26 CL CL2018000232A patent/CL2018000232A1/es unknown
- 2018-08-10 CY CY20181100846T patent/CY1120578T1/el unknown
-
2019
- 2019-03-20 AU AU2019201937A patent/AU2019201937B2/en not_active Ceased
- 2019-10-04 JP JP2019183442A patent/JP2020023525A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016127327A (ru) | Смесь пептидов | |
| JP2017502081A5 (enExample) | ||
| RU2018101225A (ru) | Мутированные фрагменты белка ras | |
| RU2016147527A (ru) | Пептидная вакцина, включающая пептид ras, содержащий мутации, и химиотерапевтический агент | |
| Butterfield et al. | Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations | |
| Okusaka et al. | Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines | |
| Türeci et al. | Targeting the heterogeneity of cancer with individualized neoepitope vaccines | |
| JP2017514847A5 (enExample) | ||
| CL2022002836A1 (es) | Polipeptidos derivados de cancer (divisional 201902533) | |
| Drilon et al. | What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC) | |
| Chaft et al. | Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation | |
| US10568948B2 (en) | Vaccines for treatment and prevention of cancer | |
| Rappa et al. | HSP-molecular chaperones in cancer biogenesis and tumor therapy: an overview | |
| PH12017502321A1 (en) | Shared neoantigens | |
| JP2024119949A (ja) | 頭頸部扁上皮がんおよびその他のがんに対する免疫療法で使用するための新規ペプチドおよびスキャフォールド | |
| EA202190669A1 (ru) | Процесс получения вакцинной композиции | |
| MX377144B (es) | Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer. | |
| BR122023020985A2 (pt) | Formulação de comprimido sólido de um inibidor de tirosina quinase de bruton | |
| Blumenthal et al. | A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors | |
| CL2022000642A1 (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluyendo el nsclc, el sclc y otros cánceres (divisional de la solicitud no. 202000020) | |
| BR112019021094A2 (pt) | Peptídeos e combinações dos mesmos para uso na imunoterapia contra leucemias e outros cânceres | |
| Lankheet et al. | Concentrations of erlotinib in tumor tissue and plasma in non–small-cell lung cancer patients after neoadjuvant therapy | |
| JP2018537519A5 (enExample) | ||
| MX2020011793A (es) | Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer. | |
| Mahadev et al. | Clinical Outcomes and Quality of Life in Cancer Patients Undergoing Immunotherapy: A Scoping Review |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20200805 |